Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2025)
Ascentage Pharma Group International (AAPG) posted quarterly Non-Current Deffered Revenue of $916451.9 for Q4 2025, down 97.35% year-over-year from $34.6 million in Q4 2024, and down 97.35% quarter-over-quarter from $34.6 million in Q4 2024.
Powered by 
Analysis
Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2025) Analysis & Trends
Ascentage Pharma Group International's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $916451.9 for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue fell 97.35% year-over-year to $916451.9; the TTM figure through Dec 2025 stood at $916451.9 (down 97.35% YoY), while the FY2025 annual figure was $929000.0, down 97.27% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $916451.9, down from $34.6 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $34.6 million in Q4 2024, with the low at $916451.9 in Q4 2025.
- The 3-year median for Non-Current Deffered Revenue is $5.0 million (2023), against an average of $13.5 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue surged 584.95% in 2024, then sank 97.35% in 2025.
- Ascentage Pharma Group International's Non-Current Deffered Revenue stood at $5.0 million in 2023, then soared by 584.95% to $34.6 million in 2024, then plunged by 97.35% to $916451.9 in 2025.
- Business Quant data shows AAPG's Non-Current Deffered Revenue at $916451.9 in Q4 2025, $34.6 million in Q4 2024, and $5.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Ascentage Pharma Group International | 1.57 Bn | 1.29 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 916,451.90 |
| Dec 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.05 Mn |